Predict your next investment

Angel Investor (Individual)

See what CB Insights has to offer

Investments

1

About Andreas Schreiner

Andreas Schreiner Headquarter Location

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Andreas Schreiner News

Parkinson’s Disease Gene Therapies to Be Discussed on April 14

Apr 6, 2021

During the 60-minute webinar, Andreas Schreiner, MD, Vice President, Medical Affairs Neuroscience and Analgesia; and Hanna Wide, MS, Executive Director, Cell and Gene Therapy, will discuss alternate gene therapies such as opto- and chemogenetics and novel genome-editing technology as well as the use of engineered, non-replicating viral vectors, predominantly recombinant adeno-associated virus or lentivirus. Attendees will learn how to meet the requirements for surgical techniques and equipment when performing intra-CNS administration of viral vectors and operational considerations for Parkinson’s disease gene therapy studies, according to a media release from Xtalks. The free webinar will take place Wednesday, April 14, 2021 at 11am EDT (4pm BST/UK). For more information and to register, visit Xtalks .

Andreas Schreiner Investments

1 Investments

Andreas Schreiner has made 1 investments. Their latest investment was in ChargeX as part of their Angel on January 1, 2019.

CBI Logo

Andreas Schreiner Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/10/2019

Angel

ChargeX

Yes

3

Date

1/10/2019

Round

Angel

Company

ChargeX

Amount

New?

Yes

Co-Investors

Sources

3

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.